GLP-1 Therapy Before Surgery: New Guidance on Managing Aspiration Risk Mar 26, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center 1,728 views As GLP-1 receptor agonists become more common in diabetes and weight management, new concerns are emerging around how GLP-1 medications are managed before surgery
0.5 mg at 2.5 mg/mL, 1 mg at 5 mg/mL, or 2 mg at 10 mg/mL
Unlike semaglutide, which acts on only the GLP-1 receptor, tirzepatide is a dual agonist that also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor
Very low LDL (below 50-70 mg/dL) achieved through aggressive medication raises theoretical concerns about reduced hormone production, potential cognitive effects, and increased hemorrhagic stroke risk in some populations
However, for some, there is a dark side to semaglutide that includes high costs, medication shortages and the potential for severe side effects